Koay M Audrey, Woon Peng Y, Zhang Yun, Miles Lisa J, Duncan Emma L, Ralston Stuart H, Compston Juliet E, Cooper Cyrus, Keen Richard, Langdahl Bente L, MacLelland Alasdair, O'Riordan Jeffrey, Pols Huibert A, Reid David M, Uitterlinden Andre G, Wass John A H, Brown Matthew A
Institute of Musculoskeletal Sciences, University of Oxford, The Botnar Research Centre, Nuffield Orthopaedic Centre, Headington, Oxford, UK.
J Bone Miner Res. 2004 Oct;19(10):1619-27. doi: 10.1359/JBMR.040704. Epub 2004 Jul 7.
Genetic studies based on cohorts with rare and extreme bone phenotypes have shown that the LRP5 gene is an important genetic modulator of BMD. Using family-based and case-control approaches, this study examines the role of the LRP5 gene in determining normal population variation of BMD and describes significant association and suggestive linkage between LRP5 gene polymorphisms and BMD in >900 individuals with a broad range of BMD.
Osteoporosis is a common, highly heritable condition determined by complex interactions of genetic and environmental etiologies. Genetic factors alone can account for 50-80% of the interindividual variation in BMD. Mutations in the LRP5 gene on chromosome 11q12-13 have been associated with rare syndromes characterized by extremely low or high BMD, but little is known about the contribution of this gene to the development of osteoporosis and determination of BMD in a normal population.
To examine the entire spectrum of low to high BMD, 152 osteoporotic probands, their families (597 individuals), and 160 women with elevated BMD (T score > 2.5) were recruited. BMD at the lumbar spine, femoral neck, and hip were measured in each subject using DXA.
PAGE sequencing of the LRP5 gene revealed 10 single nucleotide polymorphisms (SNPs), 8 of which had allele frequencies of >5%, in exons 8, 9, 10, 15, and 18 and in introns 6, 7, and 21. Within families, a strong association was observed between an SNP at nucleotide C171346A in intron 21 and total hip BMD (p < 1 x 10(-5) in men only, p = 0.0019 in both men and women). This association was also observed in comparisons of osteoporotic probands and unrelated elevated BMD in women (p = 0.03), along with associations with markers in exons 8 (C135242T, p = 0.007) and 9 (C141759T, p = 0.02). Haplotypes composed of two to three of the SNPs G121513A, C135242T, G138351A, and C141759T were strongly associated with BMD when comparing osteoporotic probands and high BMD cases (p < 0.003). An SNP at nucleotide C165215T in exon 18 was linked to BMD at the lumbar spine, femoral neck, and total hip (parametric LOD scores = 2.8, 2.5, and 2.2 and nonparametric LOD scores = 0.3, 1.1, and 2.2, respectively) but was not genetically associated with BMD variation.
These results show that common LRP5 polymorphisms contribute to the determination of BMD in the general population.
基于具有罕见和极端骨表型队列的基因研究表明,LRP5基因是骨密度(BMD)的重要基因调节因子。本研究采用基于家系和病例对照的方法,探讨LRP5基因在决定正常人群BMD变异中的作用,并描述了LRP5基因多态性与900多名具有广泛BMD范围个体的BMD之间的显著关联和提示性连锁关系。
骨质疏松症是一种常见的、高度可遗传的疾病,由遗传和环境病因的复杂相互作用决定。仅遗传因素就可占个体间BMD变异的50 - 80%。位于11q12 - 13染色体上的LRP5基因突变与以极低或极高BMD为特征的罕见综合征相关,但关于该基因对骨质疏松症发展及正常人群BMD测定的贡献知之甚少。
为研究从低到高BMD的整个范围,招募了152名骨质疏松症先证者及其家庭(597名个体),以及160名BMD升高(T值>2.5)的女性。使用双能X线吸收法(DXA)测量每个受试者腰椎、股骨颈和髋部的BMD。
LRP5基因的聚丙烯酰胺凝胶电泳(PAGE)测序在外显子8、9、10、15和18以及内含子6、7和21中揭示了10个单核苷酸多态性(SNP),其中8个等位基因频率>5%。在家族内部,内含子21中核苷酸C171346A处的一个SNP与全髋BMD之间观察到强关联(仅男性中p < 1×10⁻⁵,男性和女性中p = 0.0019)。在骨质疏松症先证者与女性中无关的BMD升高的比较中也观察到这种关联(p = 0.03),同时还与外显子8(C135242T,p = 0.007)和9(C141759T,p = 0.02)中的标记物相关。当比较骨质疏松症先证者和高BMD病例时,由两个至三个SNP G121513A、C135242T、G138351A和C141759T组成的单倍型与BMD强烈相关(p < 0.003)。外显子18中核苷酸C165215T处的一个SNP与腰椎、股骨颈和全髋的BMD连锁(参数化LOD分数分别为2.8、2.5和2.2,非参数化LOD分数分别为0.3、1.1和2.2),但与BMD变异无遗传关联。
这些结果表明常见的LRP5多态性有助于一般人群中BMD的测定。